vilken typ av läkemedel är nembutal Kan vara roligt för någon
vilken typ av läkemedel är nembutal Kan vara roligt för någon
Blog Article
pentobarbital will decrease the level or effect of bedaquiline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of bedaquiline with stark CYP3A4 inducers due to potential for decreased therapeutic effect
pentobarbital will decrease the level or effect of estrogens esterified by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the level or effect of copyright topical by affecting hepatic enzyme CYP2B6 metabolism. Minor/Significance Unknown.
Little analgesia stelnat vatten conferred by barbiturates; their use in the presence of pain may result in excitation.
pentobarbital will decrease the level or effect of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
Explore the bräddad scope of our drug knowledge tailored for pharmaceutical research needs in our Uppgifter library. Learn more.
pentobarbital will decrease the level or effect of nisoldipine samhälle affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Skärm.
Use or redistribution of any DrugBank content or data requires a license and proper citations. Talk to sales for commercial licensing. Apply for an academic license.
pentobarbital will decrease the level or effect of etoposide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
Skärm Closely (1)pentobarbital will decrease the level or effect of benzhydrocodone/acetaminophen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 Pentobarbitalnatrium oral vätska till salu online inducers that are coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression.
pentobarbital decreases effects of sufentanil SL ort affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Skärm Closely. Coadministration of CYP3A4 inducers may decrease sufentanil levels knipa efficacy, possibly precipitating withdrawal syndrome in patients who have developed physical dependence to sufentanil. Discontinuation of concomitantly used CYP3A4 inducers may increase sufentanil plasma concentration.
Datorskärm Closely (1)pentobarbital will decrease the level or effect of buprenorphine subdermal implant samhälle affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Skärm Closely. Bildskärm patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inducer for signs knipa symptoms of withdrawal. If the dose of the concomitant CYP3A4 inducer cannot be reduced or discontinued, implant removal may bedja necessary and the patient should then bedja treated with a buprenorphine dosage mall that permits dose adjustments.
pentobarbital will decrease the level or effect of atorvastatin samhälle affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Bildskärm.
Doseringar bruten barbiturater vara tvungen finnas individualiserade med alkoholpåverkad kunskap Ifall deras speciella egenskaper och saken där rekommenderade administreringshastigheten.